Adjuvant antiarrhythmic therapy in patients with implantable cardioverter defibrillators

Area of Science:

• Cardiology
• Electrophysiology
• Pharmacology

Background:

• Implantable cardioverter defibrillators (ICDs) are crucial for preventing sudden cardiac death in patients with cardiomyopathy and structural heart disease.
• Despite their benefits, patients often experience appropriate and inappropriate ICD therapies, particularly shocks, which detrimentally affect quality of life and prognosis.

Purpose of the Study:

• To review current knowledge on adjuvant antiarrhythmic drug therapy for reducing ICD shocks in patients with cardiomyopathy.
• To discuss non-antiarrhythmic drug strategies, used alone or with antiarrhythmic drugs, to mitigate the risk of subsequent ICD shocks.

Main Methods:

• Literature review focusing on antiarrhythmic and non-antiarrhythmic drug therapies in the context of ICD implantation.
• Synthesis of evidence regarding the efficacy and safety of pharmacological interventions for secondary prevention of ICD therapies.

Main Results:

• Beta-blockers and antiarrhythmic drugs are established for secondary prevention of ICD therapies, though not indicated for primary prevention.
• Adjuvant drug strategies, including non-antiarrhythmic agents, show potential in reducing the frequency of ICD shocks.

Conclusions:

• Optimizing medical therapy is essential for managing patients with ICDs and reducing the burden of shocks.
• Further research into combined pharmacological approaches may improve patient outcomes and quality of life by minimizing unnecessary ICD therapies.